Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) – Analysts at Jefferies Financial Group lowered their FY2022 earnings estimates for Ocular Therapeutix in a research report issued to clients and investors on Monday, November 7th. Jefferies Financial Group analyst C. Howerton now expects that the biopharmaceutical company will post earnings per share of ($0.92) for the year, down from their prior forecast of ($0.65). The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.87) per share. Jefferies Financial Group also issued estimates for Ocular Therapeutix’s Q4 2022 earnings at ($0.20) EPS, FY2023 earnings at ($0.81) EPS, FY2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.43) EPS and FY2026 earnings at ($0.04) EPS.
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). Ocular Therapeutix had a negative net margin of 119.35% and a negative return on equity of 78.32%. The company had revenue of $12.27 million during the quarter, compared to analyst estimates of $13.81 million.
Ocular Therapeutix Price Performance
Shares of NASDAQ:OCUL opened at $3.03 on Thursday. The firm has a market cap of $233.34 million, a PE ratio of -3.00 and a beta of 1.38. The firm’s fifty day moving average is $4.54 and its 200-day moving average is $4.28. The company has a debt-to-equity ratio of 0.80, a quick ratio of 6.08 and a current ratio of 6.14. Ocular Therapeutix has a 52 week low of $2.77 and a 52 week high of $7.57.
Insider Buying and Selling
In other news, major shareholder Summer Road Llc bought 7,328 shares of the stock in a transaction that occurred on Monday, November 7th. The stock was acquired at an average price of $3.50 per share, with a total value of $25,648.00. Following the completion of the purchase, the insider now directly owns 6,122,089 shares of the company’s stock, valued at $21,427,311.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought 166,128 shares of company stock valued at $750,000 over the last quarter. Insiders own 3.60% of the company’s stock.
Institutional Investors Weigh In On Ocular Therapeutix
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Endurant Capital Management LP increased its stake in Ocular Therapeutix by 28.8% in the first quarter. Endurant Capital Management LP now owns 923,963 shares of the biopharmaceutical company’s stock valued at $4,574,000 after purchasing an additional 206,820 shares in the last quarter. Versor Investments LP increased its stake in Ocular Therapeutix by 136.9% in the second quarter. Versor Investments LP now owns 33,400 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 19,300 shares in the last quarter. SG Americas Securities LLC bought a new stake in Ocular Therapeutix in the second quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ocular Therapeutix in the second quarter valued at $95,000. Finally, Emerald Advisers LLC increased its stake in Ocular Therapeutix by 13.5% in the second quarter. Emerald Advisers LLC now owns 1,465,702 shares of the biopharmaceutical company’s stock valued at $5,892,000 after purchasing an additional 173,797 shares in the last quarter. 57.61% of the stock is owned by institutional investors.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
- Get a free copy of the StockNews.com research report on Ocular Therapeutix (OCUL)
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Coupang Stock And Why You Should Care
- This Is No Time To Buy D.R. Horton Stock
- Tightly Held Wendy’s Is Undervalued
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.